You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Potential consequences of invasive meningococcal disease

  • Neisseria meningitidis (meningococcus) bacteria can cause invasive meningococcal disease (IMD), a rare but potentially serious infection that can lead to meningitis and/or septicemia. 1
  • In susceptible individuals, symptoms of IMD generally develop 2 to 10 days after exposure to meningococcal bacteria. 1
  • Because its signs and symptoms are nonspecific, IMD can be difficult to identify. 2
  • Despite appropriate antimicrobial treatment, up to 1 in 10 patients die, usually within 24 to 48 hours of the onset of symptoms. 13
  • Of those who recover, up to 1 in 3 patients experience long-term sequelae, such as hearing loss, neurologic disabilities, and digit or limb amputation. 1

BEXSERO is not indicated to treat or reduce the consequences of meningococcal meningitis (including meningitis, sepsis, and death) following the onset of invasive meningococcal disease.

BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains. Protection against IMD caused by other serogroups has not been studied. Therefore, protection against other serogroups should not be assumed with BEXSERO. As with any vaccine, BEXSERO may not protect all vaccine recipients.


  1. Public Health Agency of Canada. Canadian Immunization Guide Part 4. Meningococcal Vaccine. May 15, 2015. Available at: Accessed September 19, 2018.
  2. Centres for Disease Control and Prevention. Diagnosis, treatment, and complications. Available at: Accessed September 19, 2018.
  3. World Health Organization. Meningococcal meningitis fact sheet. Available at Accessed September 19, 2018.

This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit